Wall Street Reacted Dramatically To Developments At Cambridge Company
Get Breaking News First
BOSTON (CBS) – The share price for Vertex Pharmaceuticals gained an impressive 50% in trading on Monday to above $58 a share, in reaction to new clinical results for the company’s latest drug for cystic fibrosis.
WBZ NewsRadio 1030’s Anthony Silva reports.
Vertex CEO Dr. Jeffrey Leiden said the results are from a combination of two Vertex drugs. He explains the results were much more dramatic using an experimental drug.
Dr. Leiden says some 80,000 people suffer from CF in the US and Europe, and if these results hold, almost half of them could benefit from this new combination.